Cirrhosis News and Research RSS Feed - Cirrhosis News and Research

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02. [More]
Weight loss through lifestyle modifications, bariatric surgery can reduce features of NASH

Weight loss through lifestyle modifications, bariatric surgery can reduce features of NASH

Weight loss through both lifestyle modification and bariatric surgery can significantly reduce features of nonalcoholic steatohepatitis (NASH), a disease characterized by fat in the liver, according to two new studies published in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training in the gym leads to a fall in liver fat levels. This is the finding of a new study held at the University of Haifa in cooperation with Tel Aviv Medical Center and Tel Aviv University. [More]
NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Nutrition Science Initiative has launched the first-ever randomized, controlled clinical trial to determine whether removing added sugars from the diet can halt or even reverse nonalcoholic fatty liver disease (NAFLD) in children. [More]
Diabetes drug metformin can also treat portal hypertension

Diabetes drug metformin can also treat portal hypertension

The diabetes drug metformin continues to expand beyond its treatment for type 2 diabetes. In addition to its potential use in treating age-related health problems, metformin can treat portal hypertension—high blood pressure in the liver resulting from cirrhosis, according to a new study in American Journal of Physiology—Gastrointestinal and Liver Physiology. [More]
dlDNA marks progression of HBV-related liver disease

dlDNA marks progression of HBV-related liver disease

The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut. [More]

Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

A rapid, sensitive, and accurate method to detect drug resistant hepatitis C virus (HCV) mutants has been developed. Researchers at Hiroshima University established a system to rapidly and accurately measure the presence of HCV Y93H drug resistant mutant strains, and evaluate the proportion of patients harboring this mutation prior to treatment. [More]
AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

The American Association for the Study of Liver Diseases, in partnership with the Infectious Diseases Society of America and in collaboration with the International Antiviral Society-USA, created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 to aid practitioners treating patients infected with hepatitis C virus (HCV). [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
New book examines all aspects of HBV and HDV infections

New book examines all aspects of HBV and HDV infections

Despite the availability of an effective vaccine for hepatitis B, hundreds of millions of people worldwide are infected with the hepatitis B virus (HBV). This virus can cause serious liver damage and cancer in chronically infected patients. Hepatitis delta virus (HDV), a satellite of HBV, can exacerbate the disease. [More]
Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States. [More]
GSU scientists design new MRI technique for early detection of liver tumors

GSU scientists design new MRI technique for early detection of liver tumors

Scientists at Georgia State University with funding from the National Institute of Biomedical Imaging and Bioengineering have designed an imaging technique to detect early-stage liver tumors, and have proven it successful in mice. [More]
AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited. [More]
miR-181b potential biomarker of replication, progression in chronic HBV

miR-181b potential biomarker of replication, progression in chronic HBV

A Chinese team reports a correlation between serum levels of microRNA-181b and hepatitis B virus replication and disease progression in patients with chronic HBV infection. [More]
AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan. [More]
Risk prediction model can help target hepatitis C treatment to patients with most urgent need

Risk prediction model can help target hepatitis C treatment to patients with most urgent need

A team of researchers at the University of Michigan Health System has developed a risk prediction model that helps identify which hepatitis C patients have the most urgent need for new anti-viral drugs. [More]

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths. [More]
Research leads way for noninvasive detection of early stage liver cancer

Research leads way for noninvasive detection of early stage liver cancer

Led by Georgia State University, researchers have developed the first robust and noninvasive detection of early stage liver cancer and liver metastases, in addition to other liver diseases, such as cirrhosis and liver fibrosis. [More]
MD Anderson researchers find significant clinical variations among liver cancer patients

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center. [More]
Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Advertisement
Advertisement